search
Back to results

Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)

Primary Purpose

Diaphragmatic Hernia

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Placement of the GOLDBAL2 balloon
Sponsored by
Vincent Duron
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diaphragmatic Hernia focused on measuring Fetal Endoscopic Tracheal Occlusion (FETO), Congenital diaphragmatic hernia (CDH)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability (meets psychosocial criteria below) for the duration of the study Pregnant women, age 18 years and older Singleton pregnancy No pathogenic variants on microarray or pathologic findings on karyotype; results by fluorescence in situ hybridization (FISH) will be acceptable if patient is >26 weeks Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as o/e LHR <25% with liver up Gestational age at FETO procedure: if o/e LHR <25%, will be done at 27 weeks plus 0 days to 29 weeks plus 6 days Meets psychosocial criteria Willing to reside within 30 minutes of NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) and ability to maintain follow up appointments. NYP/CUIMC will work with the study participant to assist in securing housing 30 minutes from the hospital if this is a challenge to her. Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work Exclusion Criteria: Multi-fetal pregnancy History of latex allergy History of preterm labor or incompetent cervix (requiring cerclage), short cervix (<20mm), or uterine anomaly predisposing to preterm labor Psychosocial ineligibility Inability to reside within 30 minutes of NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) or inability to maintain follow up appointments Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate. Bilateral CDH, unilateral CDH with o/e LHR > 25%, or unilateral CDH with o/e LHR <25% but liver completely down in abdomen Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome Maternal contraindications to elective fetoscopic surgery Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure No safe or feasible fetoscopic approach to balloon placement Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality Participation in another intervention study that influences maternal and fetal morbidity and mortality.

Sites / Locations

  • Columbia University Irving Medical Center/NewYork-Presbyterian

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

GOLDBAL2 balloon will be placed for Fetus diagnosed with Congenital diaphragmatic hernia (CDH) at Gestational age of 27w0d - 29w6d and retrieved at Gestational age of 34w0d to 34w 6 days

Outcomes

Primary Outcome Measures

Total number of subjects with successful placement of the balloon
Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.
Total number of subjects with successful retrieval of the balloon
Success will be defined by retrieval prior to delivery, including safe retrieval during an ex-utero intrapartum therapy (EXIT) procedure.

Secondary Outcome Measures

Change in fetal lung volume growth on prenatal MRI
Fetal MRI prior to balloon placement and 2nd fetal MRI at +/- 2 weeks of balloon retrieval will be performed to calculate the difference between the 1st and 2nd MRIs.
Change in fetal lung growth on prenatal ultrasound
Fetal ultrasound before balloon placement and immediately prior to balloon removal will be performed to calculate the different between the 2 ultrasounds.
Gestational age at delivery
Gestational age at delivery will be measured.
Total number of maternal complications
Maternal complications will be recorded and reviewed.
Survival rate post-delivery
Survival rate will be measured at 180 days for those still hospitalized at the time point.

Full Information

First Posted
April 26, 2022
Last Updated
October 20, 2023
Sponsor
Vincent Duron
search

1. Study Identification

Unique Protocol Identification Number
NCT05354505
Brief Title
Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)
Official Title
Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2023 (Anticipated)
Primary Completion Date
June 2026 (Anticipated)
Study Completion Date
June 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Vincent Duron

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single site, single arm, non-randomized, pilot trial to assess the feasibility and safety of treating severe congenital diaphragmatic hernia (CDH) with Fetal Endoscopic Tracheal Occlusion (FETO) at Columbia University Irving Medical Center (CUIMC)/ NewYork-Presbyterian Hospital (NYP).
Detailed Description
Congenital diaphragmatic hernia (CDH) affects 1 in 2,200 to 5,000 live births per year. The defect in the fetal diaphragm allows abdominal organs (intestine, stomach, liver, spleen) to migrate into the thorax, hindering normal lung development. The herniated contents place pressure on the developing lungs and this may result in varying degrees of pulmonary hypoplasia and associated pulmonary hypertension; both of which may be lethal. In an attempt to prenatally quantify the impact of the herniated organs on underlying lung development, prognostic tools have been developed. The most widely used prognostic indicator is lung-to-head ratio (LHR) as measured by prenatal ultrasound. The lung contralateral to the diaphragmatic defect is measured in a transverse plane at the level of the four chamber heart and its area is divided by the fetal head circumference (LHR). The LHR is tracked through the pregnancy but seems to be most strongly correlated with outcomes in the early third trimester. Fetuses with severe CDH have a high risk of mortality. The current standard of care treatment offers postnatal repair, which is associated with overall survival of 71% in all cases. A majority (68%) of fetuses are prenatally diagnosed, and the survival in this cohort is even lower at 65%. The severity of the defect can be measured prenatally by the degree of pulmonary hypoplasia, and the survival drops to below 30% for those with expected lung volumes below 30% of expected. The purpose of the FETO procedure in severe CDH patients is to improve prenatal lung growth in order to potentially increase neonatal survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diaphragmatic Hernia
Keywords
Fetal Endoscopic Tracheal Occlusion (FETO), Congenital diaphragmatic hernia (CDH)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
GOLDBAL2 balloon will be placed for Fetus diagnosed with Congenital diaphragmatic hernia (CDH) at Gestational age of 27w0d - 29w6d and retrieved at Gestational age of 34w0d to 34w 6 days
Intervention Type
Device
Intervention Name(s)
Placement of the GOLDBAL2 balloon
Intervention Description
The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
Primary Outcome Measure Information:
Title
Total number of subjects with successful placement of the balloon
Description
Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.
Time Frame
Up to 30 weeks
Title
Total number of subjects with successful retrieval of the balloon
Description
Success will be defined by retrieval prior to delivery, including safe retrieval during an ex-utero intrapartum therapy (EXIT) procedure.
Time Frame
Up to 35 weeks
Secondary Outcome Measure Information:
Title
Change in fetal lung volume growth on prenatal MRI
Description
Fetal MRI prior to balloon placement and 2nd fetal MRI at +/- 2 weeks of balloon retrieval will be performed to calculate the difference between the 1st and 2nd MRIs.
Time Frame
Baseline and up to 37 weeks
Title
Change in fetal lung growth on prenatal ultrasound
Description
Fetal ultrasound before balloon placement and immediately prior to balloon removal will be performed to calculate the different between the 2 ultrasounds.
Time Frame
Baseline and up to 35 weeks
Title
Gestational age at delivery
Description
Gestational age at delivery will be measured.
Time Frame
At the time of delivery (up to 40 weeks of gestation)
Title
Total number of maternal complications
Description
Maternal complications will be recorded and reviewed.
Time Frame
Up to 6 weeks post-delivery
Title
Survival rate post-delivery
Description
Survival rate will be measured at 180 days for those still hospitalized at the time point.
Time Frame
Up to 180 days post-delivery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability (meets psychosocial criteria below) for the duration of the study Pregnant women, age 18 years and older Singleton pregnancy No pathogenic variants on microarray or pathologic findings on karyotype; results by fluorescence in situ hybridization (FISH) will be acceptable if patient is >26 weeks Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as o/e LHR <25% with liver up Gestational age at FETO procedure: if o/e LHR <25%, will be done at 27 weeks plus 0 days to 29 weeks plus 6 days Meets psychosocial criteria Willing to reside within 30 minutes of NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) and ability to maintain follow up appointments. NYP/CUIMC will work with the study participant to assist in securing housing 30 minutes from the hospital if this is a challenge to her. Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work Exclusion Criteria: Multi-fetal pregnancy History of latex allergy History of preterm labor or incompetent cervix (requiring cerclage), short cervix (<20mm), or uterine anomaly predisposing to preterm labor Psychosocial ineligibility Inability to reside within 30 minutes of NewYork-Presbyterian Sloane Hospital for Women/Columbia University Irving Medical Center (CUIMC) or inability to maintain follow up appointments Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate. Bilateral CDH, unilateral CDH with o/e LHR > 25%, or unilateral CDH with o/e LHR <25% but liver completely down in abdomen Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome Maternal contraindications to elective fetoscopic surgery Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure No safe or feasible fetoscopic approach to balloon placement Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality Participation in another intervention study that influences maternal and fetal morbidity and mortality.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amanda Alonso, MHA
Phone
212-342-0261
Email
aa2974@cumc.columbia.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincent Duron, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Irving Medical Center/NewYork-Presbyterian
City
New York
State/Province
New York
ZIP/Postal Code
11021
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Alonso, MHA
Phone
212-342-0261
Email
aa2974@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Vincent Duron, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)

We'll reach out to this number within 24 hrs